α1-adrenergic receptor regulation: Basic science and clinical implications

Pharmacology and Therapeutics

Volumn 88, Issue 3, 2000, Pages 281-309

  Michelotti, Gregory A ^a   Price, David T ^a   Schwinn, Debra A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adrenergic receptor; Alpha 1; Hyperplasia; Hypertrophy; Structure function; Transcription

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYLURAPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; BETAXOLOL; CLONIDINE; CYCLAZOCINE; DEXMEDETOMIDINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IDAZOXAN; INDORAMIN; METOPROLOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NIGULDIPINE; PHENTOLAMINE; PINDOLOL; PRAZOSIN; RAUWOLSCINE; RECEPTOR SUBTYPE; SALBUTAMOL; SPIPERONE; TAMSULOSIN; TERAZOSIN; UNINDEXED DRUG; YOHIMBINE;

DESENSITIZATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INTERNALIZATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARDIOMYOPATHY, HYPERTROPHIC; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 0034452038     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00092-9     Document Type: Review

References (242)

1. Benign prostatic hyperplasia poorly correlated with symptoms
2. Enhanced Gaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure
3. Study of adrenotropic receptors
4. Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling
5. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy
6. Acute mesenteric ischemia after cardiopulmonary bypass
7. Prostatism: The correlation between symptoms, cystometric, and urodynamic findings
8. Receptor-effector coupling pathway for alpha 1-adrenergic modulation of abnormal automaticity in 'ischemic' canine Purkinje fibers
9. Responses to norepinephrine of normal and 'ischemic' canine Purkinje fibers are consistent with activation of different alpha 1-receptor subtypes
10. 1-adrenergic receptor signaling in cardiac cells
11. Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs
12. Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts
13. 2-adrenergic receptor subtypes in human tissues: Evidence for species heterogeneity and implications for human pharmacology
14. 3-adrenergic receptor mRNA in human tissue
15. Effect of alpha 1-adrenergic receptor antagonists on susceptibility to malignant arrhythmias: Protection from ventricular fibrillation
16. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase
17. Acute depression of myocardial β-adrenergic receptor signaling during cardiopulmonary bypass: Impairment of the adenylyl cyclase moiety
18. Alpha 1-adrenergic and arginine vasopressin stimulation of inositide hydrolysis in rat hepatocytes is unaltered in senescence
19. Changes in myocardial and vascular receptors in heart failure
20. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease
21. Beta-adrenoceptors in cardiac disease
22. Adrenergic and muscarinic receptors in the human heart
23. 1-adrenoceptor-induced contractility in rat aorta is mediated by the α1D subtype
24. Desensitization of G-protein-coupled receptors in the cardiovascular system
25. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia
26. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
27. Adverse effects of alpha 1-adrenergic blocking drugs
28. Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms
29. Alpha-adrenergic blocking drugs in bladder outflow obstruction: What potential has alpha 1-adrenoceptor selectivity?
30. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia
31. Sp1-mediated transcriptional activation from the dominant promoter of the rat alpha1B adrenergic receptor gene in DDT1MF-2 cells
32. Alpha1-adrenergic receptor activation of c-fos expression in transfected rat-1 fibroblasts: Role of Ca2+
33. Alpha1-adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity
34. Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age
35. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention
36. Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha 1A-adrenoceptors
37. Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression
38. Regulation of pineal alpha1B-adrenergic receptor mRNA: Day/night rhythm and beta-adrenergic receptor/cyclic AMP control
39. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor
40. Regions of the α1-adrenergic receptor involved in coupling to phosphoinositol hydrolysis and enhanced sensitivity of biological function
41. Cellular localization and pharmacological characterization of functioning alpha-1 adrenoceptors by fluorescent ligand binding and image analysis reveals identical binding properties of clustered and diffuse populations of receptors
42. Transgenic Gaq overexpression induces cardiac contractile failure in mice
43. Alpha 1-adrenoceptor subtype selectivity: Molecular modelling and theoretical quantitative structure-affinity relationships
44. Pharmacological evidence that different α1-adrenoceptor subtypes mediate contraction in rabbit prostate and hypogastric artery
45. Specific alpha 1-adrenergic receptor subtypes modulate catecholamine-induced increases and decreases in ventricular automaticity
46. Characterization of α1D-adrenoceptor sybtype in rat myocardium, aorta and other tissues
47. Crosstalk between alpha-1A and alpha-1B adrenoceptors in neonatal rat myocardium: Implications in cardiac hypertrophy
48. Alpha1-adrenergic receptor subtypes activate different PKC isoforms in mouse heart
49. Identification of the α1D-adrenoceptor sybtype in rabbit arteries and the human saphenous vein using the polymerase chain reaction
50. Effect of different G protein-coupled receptor kinases on phosphorylation and desensitization of the alpha1B-adrenergic receptor
51. Characterization of the phosphorylation sites involved in G protein-coupled receptor kinase- and protein kinase C-mediated desensitization of the alpha1B-adrenergic receptor
52. Gq signaling in cardiac adaptation and maladaptation
53. Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction
54. Characterization of the alpha1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle
55. Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells
56. Pharmacological classification of α1-adrenoceptors mediating contractions of rabbit isolated ear artery: Comparison with rat isolated thoracic aorta
57. Computer simulations of signal transduction mechanism in alpha 1B-adrenergic and m3-muscarinic receptors
58. Adrenergic control of transmural coronary blood flow
59. Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling
60. Alpha 1B-adrenoceptor interacts with multiple sites of transglutaminase: II. Characteristics of the interaction in binding and activation
61. Molecular mechanisms of G protein-coupled receptor desensitization and resensitization
62. Transglutaminases
63. 1-adrenoceptor classification
64. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype
65. Desensitization of G protein-coupled receptors
66. Isolation and characterization of the gene encoding the rat alpha 1B adrenergic receptor
67. Transcription of the rat alpha 1B adrenergic receptor gene in liver is controlled by three promoters
68. Cell type-specific transcriptional activation and suppression of the alpha1B adrenergic receptor gene middle promoter by nuclear factor 1
69. The rat alpha 1B adrenergic receptor gene middle promoter contains multiple binding sites for sequence-specific proteins including a novel ubiquitous transcription factor
70. Transcriptional regulation of alpha(1b) adrenergic receptors (alpha(1b)AR) by nuclear factor 1 (NF1): A decline in the concentration of NF1 correlates with the downregulation of alpha(1b)AR gene expression in regenerating liver
71. Both the cyclic AMP response element and the activator protein 2 binding site mediate basal and cyclic AMP-induced transcription from the dominant promoter of the rat alpha 1B-adrenergic receptor gene in DDT1MF-2 cells
72. Histone H1 isoforms purified from rat liver bind nonspecifically to the nuclear factor 1 recognition sequence and serve as generalized transcriptional repressors
73. Effects of age on alpha 1-adrenoceptor subtypes in the heart ventricular muscle of the rat
74. Evidence of non-synaptic regulation of postpartum uterine contractility in the rat
75. Functional beta3-adrenoceptor in the human heart
76. Detrusor morphology in relation to bladder outflow obstruction and instability
77. 1-adrenergic receptor subtypes. Molecular structure, function, and signaling
78. Selective up-regulation of alpha1a-adrenergic receptor protein and mRNA in brown adipose tissue by neural and beta3-adrenergic stimulation
79. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction
80. Recent advances in the molecular pharmacology of the alpha 1-adrenergic receptors
81. Alpha1-adrenoceptor agonists and IGF-1, myocardial hypertrophic factors, regulate the Kv1.5K+ channel expression differentially in cultured newborn rat ventricular cells
82. α1-adrenoceptor responsiveness in the aging aorta
83. The expression of alpha 1 adrenoceptor subtypes changes with age in the rat aorta
84. Agonist regulation of gene expression of adrenergic receptors and G proteins
85. Subtypes of α1-adrenoceptors in rat blood vessels
86. A novel A/T-rich element mediates ANF gene expression during cardiac myocyte hypertrophy
87. Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation
88. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview
89. 2-adrenoceptor subtypes: Therapeutic implications
90. 1-adrenoceptors: Concensus update
91. Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants
92. Subtype-specific differences in subcellular localization of alpha 1-adrenoceptors: Chlorethylclonidine preferentially alkylates the accessible cell surface alpha 1-adrenoceptors irrespective of the subtype
93. Hamster alpha 1B-adrenergic receptor directly activates Gs in the transfected Chinese hamster ovary cells
94. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase
95. Expression of multiple alpha 1-adrenoceptors on vascular smooth muscle: Correlation with the regulation of contraction
96. Alpha 1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis
97. Alpha 1-adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: Role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase
98. Contrasting signaling pathways of alpha 1A- and alpha 1B-adrenergic receptor subtype activation of phosphatidylinositol 3-kinase and Ras in transfected NIH3T3 cells
99. Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding
100. Activation of the Sap-1a transcription factor by the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase
101. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a
102. Rapamycin selectively represses translation of the polypyrimidine tract mRNA family
103. Evidence for alternative splicing in hepatic alpha 1B-adrenergic receptor gene expression
104. Clinical implications of pathophysiologic changes in the midlife hypertensive patient
105. 1-adrenergic agonist and activated β-protein kinase C in hypertrophy of cardiac myocytes
106. Use of an alpha 1-blocker, YM-12617, in micturition difficulty
107. Efficacy in drug receptor theory: Outdated concept or under-valued tool?
108. Characterization of an α1d-adrenoceptor mediating the contractile response of rat aorta to noradrenaline
109. Appreciating alpha-adrenergic receptors and their role in ischemic left ventricular dysfunction
110. Aging: Changes in cardiac alpha 1-adrenoceptor responsiveness and expression
111. Stimulation by transforming growth factor-alpha of DNA synthesis and proliferation of adult rat hepatocytes in primary cultures: Modulation by alpha- and beta-adrenoceptor agonists
112. Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins
113. Functional distribution and role of alpha 1 adrenoceptor subtypes in the mesenteric vasculature of the rat
114. Truncation of the receptor carboxyl terminus impairs agonist-dependent phosphorylation and desensitization of the alpha 1B-adrenergic receptor
115. GTP hydrolysis by guinea pig liver transglutaminase
116. Different alpha-adrenoceptor subtypes mediate constriction of arterioles and venules
117. A three-state receptor model of agonist action
118. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
119. A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine
120. Cross talk between angiotensin AT1 and alpha 1-adrenergic receptors: Angiotensin II downregulates alpha 1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes
121. Myocardial alpha 1-adrenoceptor: Inotropic effect and physiologic and pathologic implications
122. Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha 1 adrenergic receptors
123. Cardiovascular control after injury
124. 1A-adrenergic receptor
125. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades
126. 1-adrenergic receptor subtypes in human detrusor
127. Noradrenaline contractions of human prostate mediated by alpha 1A- (alpha 1c-) adrenoceptor subtype
128. Different subtypes of α1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053
129. The retinylidene Schiff base counterion in bacteriorhodopsin
130. α-adrenergic approach in the medical management of benign prostatic hyperplasia
131. Identification of receptor mechanism mediating epinephrine-induced arrhythmias during halothane anesthesia in the dog
132. Constitutively active mutants of the alpha(1a)- and the alpha(1b)-adrenergic receptor subtypes reveal coupling to different signaling pathways and physiological responses in rat cardiac myocytes
133. Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features
134. The side-effects of c closporin-A and tacrolimus
135. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy
136. Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging
137. Regulation and function of the JNK subgroup of MAP kinases
138. Arrangement of transmembrane domains in adrenergic receptors. Similarity to bacteriorhodopsin
139. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
140. Cross-regulation between G-protein-coupled receptors. Activation of beta 2-adrenergic receptors increases alpha 1-adrenergic receptor mRNA levels
141. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate
142. Subtypes of α1-adrenoceptor involved in noradrenaline induced contractions of rat thoracic aorta and dog carotid artery
143. Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: Functional and binding studies
144. Involvement of protein kinase C and Src family tyrosine kinase in Galphaq/11-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase
145. Cross-talk between alpha(1B)-adrenergic receptor (alpha(1B)AR) and interleukin-6 (IL-6) signaling pathways. Activation Of alpha(1b)ar inhibits il-6-activated stat3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism
146. Prevention of cardiac hypertrophy by calcineurin inhibition: Hope or hype?
147. Vascular α-adrenoceptor affinity variation is not due to varying populations of subtypes distinguished by WB4101 and chlorethylchlonidine
148. Substitution of amino acids Asp-85, Asp-212, and Arg-82 in bacteriorhodopsin affects the proton release phase of the pump and the pK of the Schiff base
149. Phospholipase C-deltal and oxytocin receptor signalling: Evidence of its role as an effector
150. Cholinergic and adrenergic contractile properties of the canine ileocolonic junction
151. 1D-adrenergic receptor cDNA
152. 1A subtype
153. Identification of the mRNA for the novel α1d-adrenoceptor and two other α1d-adrenoceptors in vascular smooth muscle
154. The specific contribution of the novel α1d-adrenoceptor to the contraction of vascular smooth muscle
155. Alpha-adrenoceptors and vascular regulation: Molecular, pharmacologic and clinical correlates
156. Immunocytochemical localization of the alpha-1B adrenergic receptor and the contribution of this and other subtypes to vascular smooth muscle contraction: Analysis with selective ligands and antisense oligonucleotides
157. Characterization of α-adrenoceptor gene expression in arterial and venous smooth muscle
158. G protein-coupled receptor kinases
159. Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity
160. Influence of a lysine 331 counterion on the pK(a) of aspartic acid 125: Evidence for a salt-bridge interaction and role in alpha(1b)-adrenergic receptor activation
161. Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint
162. The agonism and synergistic potentiation of weak partial agonists by triethylamine in alpha 1-adrenergic receptor activation: Evidence for a salt bridge as the initiating process
163. Mechanisms undrlying human alpha-1a desensitization
164. 1-adrenergic receptor subtypes in human prostate
165. 1-adrenergic subtype classification
166. 1-adrenergic subtypes in human tissues: Implications for human α-adrenergic physiology
167. Genomic organization and expression of the human alpha1B-adrenergic receptor
168. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy
169. 1a-adrenergic receptor gene: Characterization of the 5′-regulatory and promoter region
170. Vasoactive mediators and splanchnic perfusion
171. Alpha-adrenergic blockade in diagnosis of detrusor instability secondary to infravesical obstruction
172. Alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes
173. Constitutively active mutants of rhodopsin
174. G protein-coupled receptors: Functional and mechanistic insights through altered gene expression
175. The developmental and physiological consequences of disrupted genes encoding beta1 and beta2 adrenoceptors
176. 1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo
177. Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes
178. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age
179. Distribution and function of peripheral α-adrenoceptors in the cardiovascular system
180. Pharmacologic and therapeutic applications of alpha2-adrenoceptor subtypes
181. Alpha- and beta-adrenoceptors: From the gene to the clinic: 2. Structure-activity relationships and therapeutic applications
182. αq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways
183. Glutamic acid-113 serves as the retinylidene Schiff base counterion in bovine rhodopsin
184. Rat vena cava α1-adrenoceptors: Characterization of [3H] prazosin binding and contraction experiments
185. Transcriptional regulation of alpha-1 adrenergic receptors
186. The activation process of the alpha1B-adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate
187. Structure of rhodopsin
188. Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: Potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression
189. Molecular pharmacology of human alpha1-adrenergic receptors: Unique features of the alpha 1a-subtype
190. Molecular cloning and expression of the cDNA for a novel α-adrenergic receptor subtype
191. 1-adrenergic receptor family
192. The alpha 1C-adrenergic receptor: Characterization of signal transduction pathways and mammalian tissue heterogeneity
193. Cloning and pharmacological characterization of human alpha1 adrenergic receptors: Sequence corrections and direct comparison with other species homologues
194. The α-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways
195. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women
196. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic BPH
197. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells: Cross striations, ultrastructure, and chronotropic response to isoproterenol
198. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines
199. Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation
200. New developments in adrenergic receptor pharmacology: Molecular mechanisms and clinical relevance
201. Roles of mitogen-activated protein kinases and protein kinase C in alpha(1A)-adrenoceptor-mediated stimulation of the sarcolemmal Na(+)-H(+) exchanger
202. Differential regulation of the mitogen-activated protein and stress-activated protein kinase cascades by adrenergic agonists in quiescent and regenerating adult rat hepatocytes
203. 2-adrenergic receptor subtypes at four distinct levels
204. 1-adrenergic subtypes at four distinct levels
205. Alpha 1-adrenoceptor subtypes in rat aorta and mesenteric small arteries are preserved during left ventricular dysfunction post-myocardial infarction
206. Effect of bladder outlet obstruction on micturition reflex pathways in the rat
207. Calcium channel antagonists prevent urinary bladder growth and neuroplasticity following mechanical stress
208. Voiding dysfunction: Diagnosis, classification, and management
209. Acquisition by innervated cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha 1-receptor
210. Cloning of the rat alpha 1C-adrenergic receptor from cardiac myocytes. Alpha 1C, alpha 1B, and alpha 1D mRNAs are present in cardiac myocytes but not in cardiac fibroblasts
211. Cloning of human RTEF-1, a transcriptional enhancer factor-1-related gene preferentially expressed in skeletal muscle: Evidence for an ancient multigene family
212. Transcription factor RTEF-1 mediates alpha1-adrenergic reactivation of the fetal gene program in cardiac myocytes
213. Structure and function of G protein-coupled receptors
214. Signaling in myocardial hypertrophy: Life after calcineurin?
215. Two pharmacologically distinct α1-adrenoceptor subtypes in the contraction of rabbit aorta: Each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role
216. Cloning, functional expression and tissue distribution of rabbit α1d-adrenoceptor
217. Epinephrine increases the severity of postresuscitation myocardial dysfunction
218. Cardiac alpha 1-adrenoceptors: An overview
219. Comparison of agonist-induced changes in beta- and alpha 1-adrenergic receptors of DDT1 MF-2 cells
220. Ischemic preconditioning in humans: Models, mediators, and clinical relevance
221. Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy
222. 1A subtypes
223. 1A subtypes
224. 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate
225. A mutation in the hamster alpha1B-adrenergic receptor that differentiates two steps in the pathway of receptor internalization
226. 1D-adrenoceptors play little role in the positive inotropic action of phenylephrine
227. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
228. Paradoxic bradycardia (vasodepressor reaction) induced by inferior vena cava occlusion: The role of alpha- and beta-adrenergic receptors and their interaction
229. Alpha 1-adrenergic stimulation inhibits 3,5,3′-triiodothyronine-induced expression of the rat heart sarcoplasmic reticulum Ca2+ adenosine triphosphatase gene
230. Vasoactive responses of a human cystic artery: Adrenoceptor characterization
231. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes
232. Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle
233. Platelet-derived growth factor inhibits alpha1D-adrenergic receptor expression in vascular smooth muscle cells in vitro and ex vivo
234. Platelet-derived growth factor-BB inhibits rat alpha1D-adrenergic receptor gene expression in vascular smooth muscle cells by inducing AP-2-like protein binding to alpha1D proximal promoter region
235. Alterations of mRNA levels of alpha 1-adrenoceptor subtypes with maturation and ageing in different rat blood vessels
236. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors
237. Voiding function: Relevant anatomy, physiology, pharmacology, and molecular aspects
238. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression
239. Regulation of alpha 1-, beta 1-, and beta 2-adrenergic receptors in rat heart by norepinephrine
240. Cloning, cell-type specificity, and regulatory function of the mouse alpha(1B)-adrenergic receptor promoter